ReviewWorld journal of hepatology2015
Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs.
Review in World journal of hepatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 74 citations in OpenAlex.
- Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.RMD open · 2020Trial
- The association of uveitis with hepatitis B and hepatitis C viruses: a large-scale population-based study.Eye (London, England) · 2023Article
- Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection.Clinical drug investigation · 2022Article
- Hydro-ethanol extract of Holarrhena floribunda stem bark exhibits anti-anaphylactic and anti-oedematogenic effects in murine models of acute inflammation.BMC complementary medicine and therapies · 2022Article
- The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review.CNS drugs · 2021Review
- Anti-Rheumatic Effect of Antisense Oligonucleotide Cytos-11 Targeting TNF-α Expression.International journal of molecular sciences · 2021Article
- Potential Effects of Coronaviruses on the Liver: An Update.Frontiers in medicine · 2021Review
- Isolated Anti-HBc: Significance and Management.Journal of clinical medicine · 2020Review
- Perioperative Management of Patients With Ankylosing Spondylitis Undergoing Spine Surgery.Frontiers in pharmacology · 2020Article
- Abatacept induced granulomatous hepatitis with a sarcoidosis- like reaction: a blinded trial in mice.BMC pharmacology & toxicology · 2019Article
- Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis.Open forum infectious diseases · 2019Article
- Changes in hepatitis B virus surface antibody titer and risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients undergoing biologic therapy for rheumatic diseases: a prospective cohort study.Arthritis research & therapy · 2018Article
- Modulation of T-cell responses by anti-tumor necrosis factor treatments in rheumatoid arthritis: a review.Arthritis research & therapy · 2018Review
- Reactivation rates in patients using biological agents, with resolved HBV infection or isolated anti-HBc IgG positivity.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2018Article
- Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice.Biologics : targets & therapy · 2018Review
- Analysis of Closed Claims in the Clinical Management of Rheumatoid Arthritis in Japan.Chinese medical journal · 2017Article
- Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016.Current oncology (Toronto, Ont.) · 2016Article
- Overview of Infections in the Immunocompromised Host.Microbiology spectrum · 2016Review
- B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use.Current rheumatology reports · 2015Review
- Recent Trend of Hepatitis E Virus Infection in Chiba Area, Japan: 3 of 5 Cases with Rheumatoid Arthritis.Case reports in gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis B virus (HBV) reactivation in rheumatoid arthritis (RA) patients undergoing biological therapy is not infrequent. This condition can occur in patients with chronic hepatitis B as well as in patients with resolved HBV infection. Current recommendations are mainly focused on prevention and management strategies of viral reactivation under tumor necrosis factor-α inhibitors or chimeric monoclonal antibody rituximab. In recent years, growing data concerning HBV reactivation in RA patients treated with newer biological drugs like tocilizumab and abatacept have cumulated. In this review, epidemiology, pathogenesis and natural history of HBV infection have been revised first, mainly focusing on the role that specific therapeutic targets of current biotechnological drugs play in HBV pathobiology; finally we have summarized current evidences from scientific literature, including either observational studies and case reports as well, concerning HBV reactivation under different classes of biological drugs in RA patients. Taking all these evidences into account, some practical guidelines for screening, vaccination, prophylaxis and treatment of HBV reactivation have been proposed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.